Defective interfering influenza virus confers only short-lived protection against influenza virus disease: Evidence for a role for adaptive immunity in DI virus-mediated protection in vivo  by Scott, Paul D. et al.
D
i
v
P
S
a
A
R
R
A
A
K
I
D
I
P
S
1
i
n
t
D
g
c
a
i
r
t
t
e
e
0
dVaccine 29 (2011) 6584– 6591
Contents lists available at ScienceDirect
Vaccine
j ourna l ho me  pag e: www.elsev ier .com/ locate /vacc ine
efective  interfering  inﬂuenza  virus  confers  only  short-lived  protection  against
nﬂuenza  virus  disease:  Evidence  for  a  role  for  adaptive  immunity  in  DI
irus-mediated  protection  in  vivo
aul  D.  Scott1,  Bo  Meng,  Anthony  C.  Marriott,  Andrew  J.  Easton ∗, Nigel  J.  Dimmock1
chool of Life Sciences, University of Warwick, Coventry CV4 7AL, UK
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 20 March 2011
eceived  in revised form 26 May 2011
ccepted 29 June 2011
vailable online 14 July 2011
eywords:
nﬂuenza
efective interfering
mmunity
rotection
CID
a  b  s  t  r  a  c  t
We  have  shown  earlier  that  a single  dose  of  cloned  defective  interfering  (DI)  inﬂuenza  A  virus  strongly
protects  mice  from  disease  following  a  lethal  challenge  with  different  subtypes  of inﬂuenza  A virus.  These
animals  suffered  no  clinical  disease  but  experienced  a subclinical  infection  which  rendered  them  immune
to  reinfection  with  the  same  challenge  virus.  However,  little  is  known  about  how  DI  virus  achieves  such
protection.  Here  we  investigated  the  role  of  adaptive  immunity  in  DI virus-mediated  protection  using
severe-combined  immunodeﬁcient  (SCID)  mice,  which  lack  competence  in  both  B-  and  T-cell  compart-
ments  but  retain  NK cell  activity.  SCID  mice  which  were  treated  with  DI virus  and  infected  with  inﬂuenza
virus  initially  remained  completely  well,  while  infected  litter  mates  that  received  UV-inactivated  DI  virus
became  seriously  ill and  died.  However,  after  10  days  of  good  health,  the DI virus-protected  SCID  mice
developed  a clinical  disease  that was  similar,  but  not  completely  identical,  to the acute  inﬂuenza  disease.
Disease  was  delayed  longer  by  a higher  dose  of  DI  virus.  We  excluded  the possibilities  that  the  DI  virus
load  in  the  lungs  had  declined,  that  the  DI RNA  sequence  had  changed  so  that  it no  longer  interfered  with
the  infectious  genome,  or that  infectious  virus  had  become  resistant  to  the  DI virus.  These  data  show
that  while  DI virus  provides  full  protection  from  the  acute  disease  in  the  absence  of  adaptive  immunity,
that  same  immunity  is  essential  for  clearing  the  infection.  This  indicates  that  the conventional  view  that
DI  virus-induced  protection  is  mediated  solely  by  competition  for  replication  with  the  challenge  virus  is
incorrect  for  inﬂuenza  virus.. Introduction
In the course of replication most viruses make defective-
nterfering (DI) viruses, which are virus particles composed of a
ormal set of viral proteins encapsidating a deleted version of
he viral genome. Because they lack essential genetic information,
I viruses are replication deﬁcient. Replication of the defective
enome is achieved by the presence in the same cell of a genetically
ompatible infectious genome, usually from the virus that gener-
ted the DI genome, and which provides the missing function(s)
n trans. DI virus is thus totally dependent on infectious virus for
eplication. Interference occurs when the ratio of defective: infec-
ious genomes increases to a level which results in a reduction of
he amount of infectious virus produced [1–5]. Most of our knowl-
dge comes from studies in cultured cells, but there is also limited
vidence that DI virus can protect against virus diseases in vivo
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E-mail  address: a.j.easton@warwick.ac.uk (A.J. Easton).
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[6–10]. The conventional view, developed by extrapolation from
in vitro studies, is that the protection afforded in vivo is also due
to competition between the DI and infectious viruses at the level
of genome replication. However, in those cases where in vivo pro-
tection has been seen there is little direct evidence for this or any
other mechanism.
Inﬂuenza A viruses have a genome that comprises 8 separate
segments of single stranded, negative sense RNA. DI inﬂuenza
viruses arise readily and their study has a long history extending
back over 60 years [5,11–13]. DI RNAs can potentially arise from
all viral segments, but are most commonly derived from segments
1–3. All inﬂuenza DI RNAs formed from their cognate RNA and con-
tain a large central deletion of approximately 80%, but retain the
terminal sequences which control replication and packaging. It is
hypothesized that an infectious particle packages one of each of
full-length segments 1–8, while the DI virus particle packages a DI
RNA in place of its cognate full-length RNA, plus the other 7 full
Open access under CC BY license.length RNAs. Most DI inﬂuenza virus preparations contain many
different DI RNA sequences, but it is not known if a single DI par-
ticle can contain more than one DI RNA, or if there are other DI
particles in the preparation that contain a DI RNA derived from a
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ifferent segment. The position and extent of the central deletion
n the DI RNA is highly variable so that DI RNAs originating from
ne genomic segment can have many different sequences. For all
hese reasons it has been difﬁcult to determine the relationship
etween a DI RNA sequence and the biological properties of the DI
irus [14]. We  recently solved this problem by using molecularly
r biologically cloned viruses that contain one major species of DI
NA [14–18], and subsequently characterized one DI virus, con-
aining RNA 244, that strongly protects mice from clinical disease
aused by various inﬂuenza A virus subtypes [18]. However, it is
ot understood how inﬂuenza DI virus mediates such protection
n vivo. In principle, DI viruses could act in vivo by interfering with
he production of homologous virus (as described above), by stimu-
ating adaptive immune responses, by stimulating innate immune
esponses, or by means as yet unknown. More than one of these
echanisms may  operate at any one time. We  have shown previ-
usly that various aspects of the humoral and T cell-mediated arms
f murine adaptive immunity interact with infectious virus in the
resence of non-cloned DI inﬂuenza A virus. The data showed that
he responses to infection were modiﬁed in several unusual ways
y the presence of active DI virus (see Section 4) [19–25]. Here
e investigate how severe combined immunodeﬁcient (SCID) mice
hat completely lack adaptive immunity but retain NK cell activity
espond to a mixture of infectious virus and in conjunction with
reatment with cloned DI virus that confers protection from disease
n immune-competent animals. SCID mice have been used exten-
ively for investigating the role of the immune system in recovery
rom inﬂuenza virus infections [26–31].
Analysis of the mechanism(s) by which DI viruses prevent dis-
ase in treated animals is not fully understood. The DI inﬂuenza
irus particle and its component proteins are indistinguishable
rom those of infectious virus and, in principle, they may  be capable
f stimulating a similar adaptive immunity as to that resulting from
xposure seen with to a conventional inactivated inﬂuenza virus
accines. The data show that adaptive immunity is not required
or DI virus to protect SCID mice from acute inﬂuenza. However,
n contrast to immune-competent animals, a delayed onset disease
ccurred about 1 week later, indicating that adaptive immunity is
equired to act in concert with DI virus to clear the infection.
.  Materials and methods
.1.  Production of 244 DI virus by reverse genetics
The 244 DI RNA used here to protect mice was originally gener-
ted spontaneously during transfection of 293T cells with plasmids
32] to make infectious inﬂuenza A/PR/8/34 [18]. After 24 h, the
93T cells were trypsinized, mixed with MDCK cells and re-plated,
nd culture supernatants harvested 7 days later. Resulting virus
as passaged twice in embryonated chicken’s eggs. The resulting
ixture of 244 DI virus, packaged in a A/PR8 particle, and infec-
ious helper A/PR8 virus was puriﬁed by differential centrifugation
hrough sucrose. Stocks were resuspended in PBS containing 0.1%
w/v) bovine serum albumin, standardized by haemagglutination
itration, and stored in liquid nitrogen. Before inoculation into mice,
elper virus infectivity was eliminated with a short burst (40 s) of
V irradiation at 253.7 nm (0.64 mW/cm2). This is referred to as
active DI virus’. The UV inactivation target is viral RNA, and UV has
ittle effect on the DI RNA because of its small target size, 395 nt
ompared with 13,600 nt for infectious virus. Longer UV irradia-
ion (8 min) inactivated mouse-protecting activity and provided a
reparation that controlled for any immune system-stimulating
r receptor-blocking effects (‘inactivated DI virus’). However, UV
reatment did not completely destroy all DI RNA. UV did not affect
aemagglutinin or neuraminidase activities. (2011) 6584– 6591 6585
2.2.  Mice
We  used wild type C3H/He-mg (H-2k) mice (bred in-house),
wild type Balb/c (H-2d) mice (Harlan UK Ltd.), and mutant
Balb/cJHanTMHsd-Prkdcscid mice (Harlan) with a defect in the Prkdc
gene which encodes DNA-PK. This leads to aberrant VDJ recombi-
nation and hence deﬁcient B and T cells. SCID mice have a normal
complement of NK cells. Wild-type Balb/c mice required 2 × 103 ffu
of WSN  challenge virus to cause consistent but non-lethal clinical
disease; this was  twice the dose needed for C3H/He-mg mice [18].
Balb/cscid mice were also infected with 2 × 103 ffu of WSN. Adult
mice (4–6 weeks old) were inoculated intranasally under light ether
anaesthesia as previously described [33,34], with a 40-l inoculum
divided between the two  nares. Mice were given various combina-
tions of active DI virus, UV-inactivated DI virus, infectious challenge
virus (A/WSN), or diluent. Infectious challenge viruses were titrated
in mice to determine a dose for each that caused comparable res-
piratory disease. The health of mice was assessed clinically and by
change in group weight [33]. Clinical criteria were scored as fol-
lows: 1 point for each healthy mouse; 2 points for a mouse showing
signs of malaise, including some piloerection, slightly changed gait,
and increased ambulation; 3 points for a mouse showing signs of
strong piloerection, constricted abdomen, changed gait, periods of
inactivity, increased breathing rate, and sometime râles; 4 points
for a mouse with enhanced characteristics of the previous group,
but showing little activity, and becoming moribund; such mice
were culled when it was clear that they would not survive; and
5 points for a dead mouse. To allow comparison, the total clini-
cal score was divided by the number of mice in the experimental
group. Lungs were scored for consolidation by estimating the per-
centage of the lung surface that had developed a plum-coloured
discoloration. They were stored post-mortem at −70 ◦C, and later
examined for virus infectivity, virion RNA, and 244 DI RNA. Animal
experiments were approved by the University of Warwick’s Ethi-
cal Review Committee and the UK Home Ofﬁce, and followed the
guidelines of the UK Coordinating Committee for Cancer Research.
2.3. Quantitative PCR
RNA  was  extracted from the left lungs of mice by grind-
ing with sterile sand and Trizol (Invitrogen). Quantitative real
time PCR was  performed on an ABI prism 7000 to quanti-
tate virion-sense (RNA−) in infected mouse lung. We  used the
following primers and probes: segment 1 F (5′ TGCAATGGGACTGA-
GAATTAGCT 3′), segment 1R (5′ TCCGCTTGTTCTCTTAAATGTGAAT
3′) and probe (5′ VIC-CACCAAAACTGAAGGAT 3′); 244 1F (5′
CATAATCAAGAAGTACACATCAGGAAGAC 3′), 244 1R (5′ CTCTTTGC-
CCAGAATGAGGAAT 3′) and probe (5′ FAM-CCCTCAGTCTTCTCC
3′); segment 7 1F (5′ CTTCTAACCGAGGTCGAAACGTA 3′), segment
7 1R (5′ GGATTGGTCTTGTCTTTAGCCA 3′) and probe (5′ FAM-
CTCGGCTTTGAGGGGGCCTGA 3′) [35]. Primers were synthesized
by Invitrogen, and the probes by ABI. To distinguish the 244 seg-
ment 1 DI RNA from full-length segment 1, a probe was designed
to cover the DI RNA junction region formed when the terminal
segment 1 fragments were ligated, and which is absent from full-
length RNA. A unique segment 1 probe was designed from the
region which has been deleted from 244 DI RNA. A standard for
each virion-sense RNA stock was  made by subcloning PCR prod-
ucts of either full length RNA or the region ﬂanking the amplicon in
pGEMT-easy vector (Promega). RNA was  transcribed using the T7 or
SP6 RNA polymerase (MEGAscript, Ambion), the mix  was  digested
with DNase I, and RNA puriﬁed by electro-elution. After ethanol
precipitation, RNA was resuspended into RNase-free water and
quantitated on a Nanodrop 1000 (Thermoscientiﬁc, Wilmington,
DE). Standard curves were generated by performing 10-fold serial
dilutions of known RNA copy numbers with each dilution assayed
6586 P.D.  Scott et al. / Vaccine 29 (2011) 6584– 6591
Fig. 1. Protection of SCID Balb/c mice by different doses of DI virus. Wild type (wt) Balb/c and Balb/cJHanTMHsd-Prkdcscid (SCID) mice were inoculated with inactivated DI
virus + A/WSN, active DI virus + A/WSN, A/WSN, DI virus, or diluent. Mice were monitored daily for weight change (left-hand panels) and clinical assessment (right-hand
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 with 12 g of DI virus or inactivated DI virus: () active DI virus + A/WSN; () ina
re  representative of two  separate experiments.
n triplicate. The reaction was conducted at 50 ◦C for 2 min, 95 ◦C for
0 min, then 40 cycles of 94 ◦C for 15 sec followed by 60 ◦C for 1 min.
.4. Infectivity assay
The  right-hand lung from each infected mouse was
omogenised with sand in PBS containing 0.1% (w/v) BSA,
nd centrifuged to remove debris. A/WSN infectivity was  titrated
n a focus-forming assay using MDCK cells in 96-well plates in
riplicate. Cells were incubated at 33 ◦C for 18 h, ﬁxed in 4% (v/v)
ormaldehyde, and blocked with 5% (w/v) milk powder in PBS.
irus-positive cells were detected using a mouse monoclonal
ntibody speciﬁc for the A/WSN haemagglutinin, and a goat
nti-mouse IgG–alkaline phosphatase conjugate (Sigma), both in
uffered saline containing 0.1% (v/v) Tween, and ﬁnally incubated
ith an alkaline phosphatase substrate (NBT/BCIP in TMN  buffer;
igma). At least 50 stained cells (foci) at an appropriate dilution
ere counted in each of three wells and averaged to give a titre in
ocus-forming units (FFU)/lung.
.  Results
.1. SCID mice are protected from acute inﬂuenza by DI virus, but
ventually  develop a delayed onset disease
Before examining SCID mice we tested the infection param-
ters of A/WSN in the immune competent Balb/c strain fromere treated with 1.2 g of DI virus or inactivated DI virus, and mice in panels e to
ed DI virus + A/WSN; () A/WSN alone; () active DI virus alone; (©) diluent. Data
which  they had been derived. Mice inoculated simultaneously
with 1.2 g of active DI virus and infected with A/WSN were
either completely protected or suffered only a mild clinical dis-
ease of short duration with slight weight loss (Fig. 1a and
b). In contrast mice inoculated simultaneously with the same
amount of inactivated DI virus and A/WSN lost 19% of body
weight at the peak of infection (Fig. 1a); all became seriously ill
but then recovered (Fig. 1b). After recovery mice in all groups
remained healthy and continued to gain weight with no unto-
ward signs for the duration of the experiment (19 days). Such
mice were immune to rechallenge with high dose A/WSN [18]
(data not shown). There was essentially no difference in disease
progression between mice inoculated intranasally with A/WSN
and mice inoculated with inactivated DI virus + A/WSN (data not
shown).
SCID mice infected with A/WSN succumbed to a disease similar
to that seen in immune-competent Balb/c mice as judged by clini-
cal signs and weight loss from day 3 after infection, progressing to
death or to the point at which they had to be euthanized (Fig. 1c and
d). The dynamics of disease were very similar in SCID mice inocu-
lated intranasally with 1.2 g (Fig. 1c and d) or 12 g (Fig. 1e and
f) of inactivated DI virus + A/WSN. However, mice inoculated with
active DI virus + A/WSN remained healthy over this period, showing
no clinical signs of disease or weight loss. These data demonstrate
that the active DI virus can protect SCID mice against acute disease
and that the adaptive immune response plays no signiﬁcant role
over the ﬁrst few days of the infection.
P.D. Scott et al. / Vaccine 29 (2011) 6584– 6591 6587
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iig. 2. Protection of SCID mice by DI virus monitored by lung infectivity and cons
r 1.2 g of inactivated DI virus + A/WSN as described in Fig. 1. Mice were monito
nfectivity (d): () active DI virus + A/WSN; () inactivated DI virus + A/WSN; () A/
SCID mice which had been protected from inﬂuenza by treat-
ent with 1.2 g of active DI virus all remained well for 9 days, but
n day 10 some started to lose weight and show signs of disease
Fig. 1c and d). The mice developed severe respiratory symptoms
nd continued weight loss and progressed to death or euthanasia
Fig. 1c and d). SCID mice treated with a higher DI dose (12 g)
emained well for 14 days, but started to lose weight and become
ll on day 15 (Fig. 1e and f). At both doses the delayed onset disease
ad similar dynamics in terms of clinical signs, severity, and dura-
ion to the acute inﬂuenza seen in SCID mice infected with virus
lone. This indicates that the adaptive immune response plays an
mportant role in the late stages of DI virus-mediated protection
rom inﬂuenza virus infection in vivo.
.2. DI virus retards lung consolidation and accumulation of
nfectious  virus load in the lungs of SCID mice.
To understand how DI virus mediated protection we examined
ice for lung consolidation and lung infectivity. Protection con-
erred by 1.2 g of active DI virus (Fig. 2a and b) closely reproduced
ata shown in Fig. 1. Lungs of SCID mice inoculated with A/WSN
nly or with inactivated DI virus + A/WSN showed signs of consoli-
ation from day 4 onwards, with lungs exhibiting a plum-coloured
iscoloration of small areas of the lung surface, particularly around
he insertion of the bronchi (Fig. 2c). This looked very similar to
he lungs of immune-competent mice infected with A/WSN. Con-
olidation increased rapidly until, by day 6, the majority of the
ung surface was discoloured. During this period there was  no sign
f consolidation in the lungs of active DI virus-treated, infected
ice, but consolidation developed in these animals from day 8. The
iming was atypical as the delayed consolidation appeared 3 days
efore the onset of clinical disease or weight loss instead of 1 to 2
ays afterwards seen with the normal acute disease (Table 1). Lung
onsolidation in active DI virus-treated, virus-infected SCID mice
rogressed at a similar rate to that in SCID mice given only infec-
ious virus. Consolidation declined in the few active DI virus-treated
ice that survived to day 16.
On day 2 post-infection the lung infectivity in SCID mice
noculated with inactivated DI virus + A/WSN was already 10% ofion. Mice were inoculated with combinations of 1.2 g of active DI virus + A/WSN
ily for weight change (a), clinical assessment (b), lung consolidation (c) and lung
lone; () active DI virus alone; (©) diluent.
the maximum value reached on day 4, while the lung titre in
mice receiving active DI virus + A/WSN was  83-fold lower on day
2. Although the infectious load in active DI virus-treated mice
increased slowly over the next few days the difference seen with
treated with active or inactive DI virus remained at over 10-fold to
day 6 post infection. At this time active DI virus-treated, infected
mice appeared perfectly normal, while mice that received inac-
tivated DI virus + A/WSN had had lost nearly 20% body mass and
were extremely ill. From days 4 to 8 the infectious load in DI
treated-mice rose steadily, and at day 8 there was overt lung con-
solidation (Fig. 2c). Consolidation, infectious virus load, weight
loss and clinical disease all increased thereafter (Fig. 2a–d). Taken
together, the data show that active DI virus treatment signiﬁcantly
delayed the production of infectious virus in the lungs of SCID
mice compared to those treated with inactive DI virus and this
correlated with delays in the lung consolidation and overt clinical
disease.
3.3. The delayed onset disease in active DI virus-treated SCID
mice  is not due to lung DI RNA declining in amount or undergoing
mutation
There  are no reports in the literature for the dynamics of
inﬂuenza full-length or DI RNA synthesis in the mouse lung. To
determine if the delayed disease was due to changes in the lev-
els of 244 DI or infectious virus RNA, total RNA was isolated from
the lungs of each group of SCID mice described in Fig. 2 and sub-
jected to real-time PCR to determine the amounts of 244 DI RNA,
genomic segment 1 RNA, and segment 7 RNA (Fig. 3). The levels of
segments 1 and 7 RNA on day 2 after infection were similar in the
lungs of mice given either inactivated DI virus + A/WSN or active
DI virus + A/WSN. On day 4 there was 5-fold less segment 7 and
12-fold less segment 1 in the active DI virus + A/WSN than in the
control group but by day 6 both groups had similar amounts of seg-
ments 1 and 7. At this point the levels of segments 1 and 7 in the
lungs of the inactivated DI virus + A/WSN group reached a plateau,
while those in the active DI virus + A/WSN group reached a plateau
from day 8. On day 8 mice in the inactivated DI + A/WSN group were
very sick indeed, and the amount of RNA in replicate lungs varied
6588 P.D.  Scott et al. / Vaccine 29 (2011) 6584– 6591
Table  1
Relationship between lung infectivity and signiﬁcant levels of clinical disease parameters.
Lung infectivity of approximately (×106 ffu/lung) Weight loss Clinical disease Lung consolidation
Acute diseasea Day 2 Day 2 Day 3 Day 4
Delayed  onset diseaseb Day 8 Day 11 Day 11 Day 8
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sa In SCID mice inoculated with 1.2 g inactivated 244 DI virus + A/WSN.
b InSCID mice inoculated with 1.2 g 244 DI virus + A/WSN.
y over 100-fold making the mean unreliable. The majority of mice
n this group died shortly thereafter. In both groups, levels of seg-
ent 7 RNA were consistently 5 to 10-fold greater than those of
egment 1. The reasons for this are unclear but as the PCR primers
re vRNA speciﬁc this appears to be a genuine difference. This is
onsistent with studies with studies of synchronized infection of
ells in vitro in which segment 7 RNA was 9-fold greater than the
ombined RNAs1 to 3 [36] or 2-fold greater than RNA 1 early in
nfection [37].
There  was an initial high level of approximately 108 copies of
44 DI RNA in the lungs of SCID mice inoculated with the active DI
irus + A/WSN, and about 100-fold lower in the group that received
nactivated DI virus + A/WSN. The latter represents UV-fragmented
44 RNA and residual intact 244 RNA (Fig. 3c and d). After 2 days
here was undetectable 244 DI RNA in the lungs of mice inocu-
ated with inactivated DI virus + A/WSN (Fig. 3c and d), whereas
he amount in the active DI virus + A/WSN group was unchanged.
44 RNA in the active DI virus-protected group then maintained modest but steady rise to nearly 109 copies per lung by day
, and remained between 108 and 109 copies until day 16 when
ost of the mice were dead. The RNA was clearly being repli-
ated as mice that received only active DI virus showed a steady
ig. 3. Quantitative RT-PCR of 244 DI RNA and full-length virion RNAs 1 and 7 isolated f
ntranasally with inactivated DI virus + A/WSN, A/WSN, DI virus, and diluent; panel (b) mi
ungs  of 2 replicate mice are shown: (v) 244 DI RNA; () segment 1 virion RNA from mice
irion RNA from mice inoculated with active DI + A/WSN or inactivated DI virus + A/WSN
egment 7 (♦). Panels (b) and (d) show data for mice inoculated with DI virus only: segmdecline  in amounts of 244 RNA (Fig. 3d open squares). Thus sub-
stantial amounts of 244 RNA were present in mice inoculated with
DI + A/WSN throughout both the initial period of good health (up
to and including day 9) and through the period of delayed onset
disease (days 10–16). In contrast 244 DI RNA in the lungs of mice
inoculated with inactivated DI virus + A/WSN increased from day
2 to day 4 reﬂecting rapid replication of residual amounts of DI
RNA that remained after the UV-irradiation (Fig. 3c). The 244 RNA
increased to a maximum on day 6, but this was evidently too late to
be of beneﬁt as 75% of mice already showed signs of clinical disease
on day 4.
Although 244 DI RNA was  replicated in the lungs of A/WSN-
infected SCID mice that were initially protected from acute disease,
it was possible that at some stage the 244 DI RNA mutated and was
no longer recognised or replicated by the A/WSN ‘helper virus’. To
address this, RNA was  isolated from the lungs of very sick SCID
mice inoculated with DI virus + A/WSN at 16 days post infection.
Sequencing conﬁrmed that there were no nucleotide changes com-
pared with the original 244 DI RNA. In addition 5′ and 3′ RACE
(rapid ampliﬁcation of cDNA ends) conﬁrmed that the terminal
sequences were also unchanged (data not shown). The same result
was  obtained in 2 independent experiments, demonstrating that
rom the lungs of mice inoculated as described in Fig. 2. Panel (a), mice inoculated
ce inoculated intranasally with active DI virus + A/WSN. Means of the data from the
 inoculated with active DI + A/WSN or inactivated DI virus + A/WSN; () segment 7
. Panel (a) also shows data for mice inoculated with WSN  only: segment 1 () and
ent 1 (), segment 7 (♦), and 244 DI RNA ().
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Fig. 4. Comparison of the ability of DI virus to protect immune-competent C3H/He-mg mice infected with SCID/WSN-DI virus or the original A/WSN challenge virus.
SCID/WSN-DI virus was isolated from SCID mice 16 days after inoculation with active DI virus + A/WSN (see Fig. 2). The latter was  given a single passage in MDCK cells and its
infectivity  titre normalized to that of A/WSN in MDCK cells. Panels (a) and (b), mice infected with SCID/WSN-DI virus; panels (c) and (d), mice infected with A/WSN. Mice were
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irus;  () 0.12 g active DI virus + infectious virus; () 1.2 g inactivated DI virus +
ther  data are as in Fig. 1.
uthentic 244 DI was present in substantial amounts in the sick
ice on day 16 after infection.
.4.  Delayed onset disease in active DI virus-treated SCID mice is
ot due to challenge virus becoming resistant to DI virus
DI  genomes are replicated by the infectious homologous virus
nd interfere with the production of infectious virus when a critical
atio of DI genomes: infectious genomes is reached. This suggests
hat there may  be evolutionary pressure for the ﬁxation of viral
utations that result in it no longer recognising, replicating or
eing inhibited by 244 DI RNA. Such resistance has been reported to
ccur in cell cultures persistently infected by VSV or Sindbis virus
38–44] but not in cells infected with inﬂuenza viruses. The latter
ight be considered unlikely as inﬂuenza virus resistant to DI virus
ould have to develop mutations in each of its 8 independently
eplicating genome segments.
To  test this possibility we isolated infectious virus from the lungs
f severely ill SCID mice at 16 days after inoculation with active
I virus + A/WSN (Fig. 1). Virus was passed once in MDCK cells (to
roduce SCID/WSN-DI virus), puriﬁed as described in Section 2, and
itrated in MDCK cells alongside the original A/WSN challenge virus.
he SCID/WSN-DI virus (Fig. 4a and b) was then compared with the
riginal A/WSN challenge virus (Fig. 4c and d) at the same infec-
ivity titre (2.8 × 103 ffu) in an in vivo protection experiment with
44 DI virus and immune competent mice. Data in Fig. 4 show that
oth viruses had similar virulence when inoculated alone or in the
resence of inactivated DI virus, and that 1.2 g of DI virus gave
imilar protection to mice infected with SCID/WSN-DI virus or the
riginal A/WSN. A further 10-fold dilution of DI virus gave reduced
ut still signiﬁcant protection. This indicates that infectious A/WSN
hat had been replicating for 16 days in the SCID mice and the origi-
al challenge virus recognized 244 DI RNA to a similar extent. Thus
he observed breakdown in protection in SCID mice was not due to
nfectious virus becoming resistant to the DI virus during rounds of
ultiplication in vivo.ange; panels (b) and (d), clinical assessment: () 1.2 g active DI virus + infectious
ious virus; () infectious virus alone; () 1.2 g active DI virus alone; (©) diluent.
4. Discussion
Intranasal inoculation with 244 DI inﬂuenza virus completely
protected SCID mice from rapid onset acute respiratory disease
caused by A/WSN over the period that control groups became
severely ill and died. Protected mice appeared completely normal
showing no sign of disease or weight loss. This demonstrated that
adaptive immune responses, in which SCID mice are totally deﬁ-
cient, are not needed for 244 DI virus-mediated protection. The
main correlates of protection from clinical disease and weight loss
in mice inoculated with active DI virus + A/WSN compared with
control receiving inactivated DI virus + A/WSN are (a) reduction in
the amount of infectious virus in the lungs of mice on day 2 (83-
fold), day 4 (27-fold) and day 6 (10-fold), (b) reduction in genomic
RNAs 1 and 7 in the lung on day 4, (c) larger amounts of 244 DI
RNA in the lung on days 2 and 4, and (d) absence of lung consolida-
tion. It appears therefore that the key events necessary to maintain
animal wellbeing occur early in infection, with the main protec-
tive action of DI virus taking place at 2 and 4 days after infection
or earlier. Protection correlated with high amounts of lung DI RNA
and low amounts of lung infectivity. Despite the relatively high
virus load in the lungs of protected mice, they appeared to be clin-
ically normal at this time, gaining weight, and exhibiting no lung
consolidation.
A summary of the main features of the delayed onset dis-
ease in SCID mice given the lower dose (1.2 g) of active 244
DI virus + A/WSN and the acute disease in SCID mice given the
same amount of inactivated 244 DI virus + A/WSN is shown in
Table 1. In the acute disease, signiﬁcant weight loss and clini-
cal signs coincided with or occurred 1 day later than infectivity
reaching approximately 106 ffu in the lung, with consolidation
commencing 1–2 days later. In contrast, mice treated with DI  virus
attained similar levels of infectivity and signiﬁcant consolidation
on day 8, but signiﬁcant weight loss and clinical signs were not
apparent for another 3 days. However, once initiated the course
of disease in the acute and late onset disease groups was indis-
tinguishable. We  have not seen any relapse in many hundreds of
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ild-type mice, with no known immune defect, protected with
44 DI virus from various inﬂuenza A viruses, and this includes
bserving most mice for 7 weeks and some for 6 months after
nfection (authors’ unpublished data). Lung consolidation in SCID
ice infected with an inﬂuenza A virus is described as plum
oloured areas on the lung surface (as we found), which microscop-
cally presents as a proliferative pneumonia, comprising a massive
ultifocal to coalescing proliferative bronchitis, bronchiolitis, and
lveolitis, marked proliferation of type II pneumocytes, and hyper-
lastic and hypertrophic columnar epithelium lining the airways
26]. A substantial migration of natural killer cells into the lungs of
nﬂuenza virus-infected SCID mice has also been reported, although
hey played no role in disease progression [27]. In mice given a
0-fold higher DI dose, disease was delayed by a further 7 days
howing that the delay was  DI virus dose-dependent (Fig. 1d and f).
on-clearance of infectivity is the norm in inﬂuenza virus-infected
CID mice [28,29,31], not unexpectedly as immune competent
ice require B and T cell responses to clear inﬂuenza infection
45–47].
Previous work using wild-type mice, A/WSN challenge virus,
nd non-cloned DI WSN  virus showed that there were MHC-
estricted virus-speciﬁc CD8+ and CD4+ CTL responses in the lungs
f H-2k mice infected with A/WSN or A/WSN + inactivated DI virus.
hese mice all died. CTL responses were diminished in mice inoc-
lated with A/WSN + DI virus and these all survived [19]. Analysis
f the speciﬁcity of T cell responses using vaccinia viruses express-
ng individual inﬂuenza A virus proteins showed that, unusually
or inﬂuenza A virus infections, the response in A/WSN-infected,
I virus-treated mice was largely strain speciﬁc. Depletion of
oth CD8+ and CD4+ cells with speciﬁc antibody was  needed to
bolish lung consolidation and for mice infected with A/WSN or
/WSN + inactivated DI virus to survive [19], but like the SCID mice
eported here, infectious virus in the lung was not cleared. In con-
rast, when mice depleted of CD8+ and CD4+ cells were inoculated
ith A/WSN + DI virus, lung infectivity was cleared, presumably
ith the assistance of local, T cell-independent, virus-speciﬁc
ntibody. These mice produced a haemagglutinin (HA)-speciﬁc
ntibody that was highly unusual as it was not neutralizing but,
hen adoptively transferred, protected naïve animals from A/WSN
20,22,25]. The same HA-speciﬁc lung IgG conferred cell killing
bility on naïve cells in a MHC  class I restricted manner [23] In
ddition, a monoclonal antibody isolated from lung B cells pos-
essed no haemagglutination-inhibition activity but recognised
A on the surface of cells only in the context of the cognate
HC class I antigen, and in so doing mimicked the speciﬁcity of
 T cell receptor [24]. Thus A/WSN + DI virus stimulated in the
ung two highly unusual HA-speciﬁc antibodies. Mice infected
ith A/WSN or A/WSN + inactivated DI virus did not make the
A-speciﬁc, non-neutralizing lung antibody. HA-speciﬁc antibody
rom the serum of the same animals was conventionally neu-
ralizing, but evidently did not enter the lung compartment. In
ummary, there are some unusual and possibly unique interactions
etween the immune system and DI virus when it is replicated in
ice. Broadly it appears that the immunomodulatory activity of
nﬂuenza A virus is modiﬁed by DI virus through its interfering
roperty to produce a generally favourable outcome for the host
nimal [21]. Whether or not different inﬂuenza A DI RNA sequences
odulate immune responses in the same way remains to be deter-
ined.
Analysis of RNA taken at day 16 from the lungs of sick SCID
ice that had received active 244 DI virus + A/WSN showed that
he sequence, and thus the properties, of the 244 RNA had not
hanged. Infectious A/WSN isolated from the same group of mice
as also unchanged in sensitivity to interference by 244 DI virus
n subsequent tests in immune competent mice in vivo. This lack
f acquired resistance to DI virus contrasts with the appearance (2011) 6584– 6591
of  oseltamivir-resistant mutants in inﬂuenza virus-infected SCID
mice [29]. It appears that while adaptive immune responses are
not needed for DI-mediated protection from acute disease, they
are essential for clearance of infectious virus and, that without
such responses, DI virus is unable to prevent disease eventually
occurring.
From days 4 to 8 there were small increases in the amounts
of infectious virus, genomic RNAs and 244 DI RNA, with all show-
ing a modest peak on day 8, and this build up appears to presage
overt late onset disease. The interactive dynamics of infectious
virus, genomic RNAs and 244 DI RNA during the initial acute
disease/protection phase are difﬁcult to reconcile with the conven-
tional dogma that protection is mediated by the DI RNA competing
for replication with cognate full-length segment 1, and thus reduc-
ing the amount of infectious virus produced. In fact, we see that
on days 2, 4 and 6 after infection, infectivity is lower in the active
DI group (by 83-, 27- and 10-fold, respectively) than in the inacti-
vated DI group as expected, but on day 2 both groups had the same
level of segment 1. Segment 1 was  reduced in the DI group only on
day 4 (by 12-fold). In addition to this quantitative disparity, there
was no preferential reduction in the cognate segment 1, as segment
7 was reduced in parallel (on day 4 by 5-fold). An intriguing fea-
ture of this work was  the constant ratio of viral segment 1 RNA:
244 RNA, a segment 1 DI RNA. We  saw no evidence of competi-
tion for replication between the DI and its cognate full-length RNA
segment in the lung. However, we do not know if these data are
affected by any asynchronicity of infection of cells by infectious and
DI virus, or by heterogeneity of cells in the lung. There is no doubt
that DI RNA is being replicated as the amount of DI RNA in lungs of
mice inoculated only with DI virus declined by over 100-fold during
the experiment. Data show that in the lung segment 1 RNA levels
increase faster than lung 244 DI RNA levels and this may  explain
why there is disease breakthrough. The lowest recorded ratio of
segment 1: DI RNA (1.3-fold) occurred on day 2 post infection, with
the maximum ratio on day 12 (32-fold). Again there is no prefer-
ential difference as the maximum ratio of segment 7: 244 RNA was
also on day 12.
Several  mechanisms have been proposed for the mode of action
of 244 DI virus in vivo including interference with the production
of homologous virus via competition between DI and full-length
genomes, stimulation of adaptive immune responses, or activation
of innate immune responses. The simplest explanation for the dis-
parity between the lung infectious virus load and lung viral genomic
RNA is that DI RNA is competing not at the level of RNA replication
but at the level of assembly or packaging of virion RNA into new
virions. The packaging of inﬂuenza virus genome RNA into virus
particles is a very speciﬁc process with the virus selectively pack-
aging one copy of each of the 8 segments [48]. Thus, packaging of
the DI RNA would prevent packaging of the segment from which
it was  derived and would very efﬁciently render that virus particle
non-infectious. The data presented here also indicate that adap-
tive immunity is not required for prevention of acute infection in
SCID mice but is needed to prevent disease breaking out later. This
was  not due to genome competition between the segment 1 DI
RNA and its cognate full-length segment. In other experiments we
have found that 244 RNA fully protects type I interferon receptor
null mice from disease resulting from A/WSN infection [49]. How-
ever, the possibility that interferon also plays a role in DI-mediated
protection of SCID mice has yet to be determined.
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